AG 013

Drug Profile

AG 013

Alternative Names: AG013; Lactococcus lactis expressing human trefoil factor 1; Lactococcus lactis secreting human trefoil factor 1; TFF1 - Intrexon; Trefoil factor 1 - Intrexon

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation; Oragenics Inc
  • Class Bacteria; Peptides
  • Mechanism of Action Mucoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stomatitis

Most Recent Events

  • 18 Jul 2017 Phase-II clinical trials in Stomatitis in USA (Topical) (NCT03234465)
  • 18 Apr 2017 Oragenics files an IND application for phase II trial with the US FDA for Oral mucositis
  • 21 Nov 2016 AG 013 receives Fast Track designation for Stomatitis (Topical, Liquid) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top